Ilia N Buhtoiarov

9PUBLICATIONS
34CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer diagnosisSolid tumoursRespiratory diseasesHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Feb 25, 2026
Comment on: Targeted Therapy in Pediatric Langerhans Cell Histiocytosis: Describing a Novel Strategy to Minimize Long-Term Exposure While Maintaining Efficacy. A Ball Gown That Fits All.

Ilia N Buhtoiarov

|Aug 28, 2025
Value of 18F-FDG PET/CT Scans in Staging and Follow-Up of Pediatric Langerhans Cell Histiocytosis: Comparison to CT and/or MRI.

Maria F Dien Esquivel, Abdullah AlMutawa, Afsaneh Amirabadi

|Apr 27, 2025
Disease response criteria in Langerhans cell histiocytosis: a global view.

Ilia N Buhtoiarov, Milen Minkov, Reza Vali

|Feb 07, 2025
Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial.

Chunmeng Wang, Xianglin Hu, Lingge Yang

|Mar 10, 2023
Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma.

Christopher J Forlenza, Jaclyn Rosenzweig, Audrey Mauguen

|Mar 26, 2022
Durable remission for four pediatric patients with high-risk relapsed classical Hodgkin lymphoma treated with brentuximab vedotin plus gemcitabine but without autologous stem cell transplantation: A report from the Children's Oncology Group.

Ilia N Buhtoiarov, Nkechi I Mba, Crystal D L Santos

Pageof 2

Frequent Collaborators

2 joint publications

Reza Vali

1 joint publications

Christopher J Forlenza

1 joint publications

Jaclyn Rosenzweig

1 joint publications

Audrey Mauguen